Oramed Pharmaceuticals Inc. (ORMP) - Q1 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended March 31, 2025. Oramed Pharmaceuticals Inc. is a biopharmaceutical company focused on oral delivery of therapeutic proteins, primarily oral insulin (ORMD-0801). The company is currently navigating a strategic pivot following the termination of previous Phase 3 trials, focusing on a revised trial (ORA-D-013-3) targeting specific patient subpopulations. A significant portion of the quarter's activity involves a proposed joint venture (JV) with Hefei Tianhui Biotech Co., Ltd. (HTIT) to form OraTech, which is currently on hold due to regulatory delays stemming from U.S.-China trade tensions.
Key Financial Metrics
| Metric | Q1 2025 | Q1 2024 |
|---|---|---|
| Revenue | $2.0 million | $0 |
| Net Income (Loss) | $(7.6) million | $1.5 million |
| Operating Loss | $(4.5) million | $(3.0) million |
| EPS (Basic & Diluted) | $(0.19) | $0.04 |
| Cash and Cash Equivalents | $74.5 million | $18.6 million |
| Total Current Assets | $131.5 million | $143.2 million |
| Total Current Liabilities | $5.5 million | $5.7 million |
| Working Capital | $126.0 million | $137.5 million |
Debt and Liquidity: The company reported no interest expenses for the quarter as short-term borrowings were fully repaid in 2024. The company holds significant investments at fair value, primarily related to the Scilex Holding Company transaction (Tranche A and B Notes), valued at approximately $29.7 million as of March 31, 2025.
Material Changes vs. Prior Period
- Revenue Recognition: Revenue of $2.0 million was recognized in Q1 2025 compared to zero in Q1 2024. This resulted from the waiver of claims by HTIT under the amended Joint Venture Agreement, allowing the recognition of previously deferred revenue from the 2015 Technology License Agreement.
- Cost of Revenue: A one-time cost of $1.987 million was recorded, primarily representing the repayment of grants to the Israel Innovation Authority (IIA) required to transfer technology to the new JV entity, OraTech.
- Operating Expenses: Research and Development (R&D) expenses increased 87% to $2.2 million, driven by preparations for the new Phase 3 trial and increased stock-based compensation. General and Administrative (G&A) expenses rose 29% to $2.3 million, also due to stock-based compensation.
- Financial Income/Expense: The company swung from a financial income of $5.1 million in Q1 2024 to a net financial expense of $2.6 million in Q1 2025. This shift was primarily due to the revaluation of investments in Scilex and marketable securities.
Guidance, Outlook, and Risks
Joint Venture Status: The closing of the JV Agreement with HTIT is currently on hold. HTIT has been unable to obtain necessary regulatory approvals due to U.S.-China trade tensions. Consequently, Oramed has paused plans to initiate the U.S. Phase 3 clinical trial pending clarity. Management is evaluating alternative partners or independent pathways.
Strategic Investments: The company is actively diversifying its capital allocation. In Q1 2025, it entered into a loan agreement for a real estate project and invested in RoyaltyVest (a JV with institutional investors) to acquire rights to Scilex products (Gloperba, Elyxyb, ZTlido) and BioXcel Therapeutics shares. In April 2025 (subsequent event), Oramed invested approximately $36.9 million in Alpha Tau Medical Ltd.
Risks:
- Regulatory/Trade Risk: Ongoing U.S.-China trade tensions pose a material risk to the HTIT joint venture and the supply chain for oral insulin.
- Clinical Risk: The success of the revised Phase 3 trial (ORA-D-013-3) is not guaranteed, despite positive subpopulation data from previous trials.
- Investment Risk: Significant portions of the company's assets are tied to the fair value of Scilex notes and warrants, which are subject to market volatility and Scilex's ability to repay.
Key Facts for Investor Verification
- JV Viability: Verify the status of HTIT's regulatory approvals and the likelihood of the OraTech spin-off proceeding as planned.
- Cash Burn Rate: Monitor the impact of the paused Phase 3 trial on future R&D expenditures and the runway provided by the $74.5 million cash balance.
- Scilex Exposure: Assess the credit risk of Scilex Holding Company regarding the Tranche A and B notes, which represent a significant portion of Oramed's investment portfolio.
- Real Estate Strategy: Evaluate the rationale and risk profile of the company's new strategy to invest up to $30 million in real estate assets and loans.
- Alpha Tau Investment: Review the terms and strategic fit of the $36.9 million investment in Alpha Tau Medical Ltd. announced in April 2025.